Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

puzzled222 Apr. 27 at 4:40 AM

$SLS 20% of 126 = 25 If 80th event happened today, we would be at 46 alive, almost double.

0 · Reply

pi22dv7 Apr. 27 at 4:38 AM

$SLS Lets hope we do a SNDK style run by EOY.

0 · Reply

Ehri Apr. 27 at 4:33 AM

$SLS So nothing will happen 'today or tomorrow' after all, just because the CEO posted the usual stuff on LinkedIn again? The silence is broken! - So, see you in Q4 2026 or 2027 for the '80th'. Just as the ML models predict.

2 · Reply

Mjohns92 Apr. 27 at 4:31 AM

$SLS Crazy this was just 4 months ago. What a wild ride it's been and will continue to be

0 · Reply

ellenroberts337 Apr. 27 at 4:27 AM

$SLS Analyst target price update for today @ellenroberts337

0 · Reply

55X_ROI_Q1_2026 Apr. 27 at 4:27 AM

$SLS Max Value -- Buyout Will Come After Gps P3 results. a positive P3 Result is worth $40B to Big Pharma... Expect this $5 Share Price to Double, at least in the run up to that Mountain of Value.

0 · Reply

WangSLO Apr. 27 at 4:21 AM

$SLS

2 · Reply

WolfCola Apr. 27 at 4:19 AM

$SLS it would have been better if the dilution was somehow tied to the success of the drug. Would have been better for morale

0 · Reply

ValueIntelligenceAnalyst Apr. 27 at 4:17 AM

$SLS biotech name with big upside potential tied to trial results and FDA progress

1 · Reply

55X_ROI_Q1_2026 Apr. 27 at 4:15 AM

$SLS

0 · Reply

These 16 stocks are a short seller's dream — likely losers no matter what the market does

EVCM LCID NNE SERV

Mar 19, 2026, 4:05 PM EDT - 5 weeks ago

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 4:30 PM EDT - 5 weeks ago

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

Mar 12, 2026, 8:35 AM EDT - 6 weeks ago

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Mar 4, 2026, 12:59 PM EST - 7 weeks ago

What's Going With SELLAS Life Sciences Stock On Wednesday?

Jan 14, 2026, 8:30 AM EST - 3 months ago

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 4 months ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 5 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Oct 29, 2025, 10:00 AM EDT - 6 months ago

SELLAS Life Sciences Group Transcript: R&D Day 2025

Oct 27, 2025, 8:30 AM EDT - 6 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 7, 2025, 8:30 AM EDT - 9 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 10 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 11 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 11 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 1 year ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 1 year ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 1 year ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 20, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Transcript: Study Update

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 2 years ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 2 years ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Transcript: Study Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 2 years ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Jan 3, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Group Transcript: Status Update

May 30, 2023, 8:00 AM EDT - 3 years ago

SELLAS Life Sciences Group Transcript: Status Update

Jan 31, 2023, 8:30 AM EST - 3 years ago

SELLAS Life Sciences Group Transcript: KOL Event

Nov 14, 2022, 8:30 AM EST - 3 years ago

SELLAS Life Sciences Group Transcript: Study Update

Sep 15, 2022, 1:00 PM EDT - 3 years ago

SELLAS Life Sciences Group Transcript: Status Update

Apr 6, 2022, 8:30 AM EDT - 4 years ago

SELLAS Life Sciences Group Transcript: Status Update

Aug 17, 2021, 1:00 PM EDT - 5 years ago

SELLAS Life Sciences Group Transcript: Status Update

Jun 3, 2021, 8:30 AM EDT - 5 years ago

SELLAS Life Sciences Group Transcript: Status Update

puzzled222 Apr. 27 at 4:40 AM

$SLS 20% of 126 = 25 If 80th event happened today, we would be at 46 alive, almost double.

0 · Reply

pi22dv7 Apr. 27 at 4:38 AM

$SLS Lets hope we do a SNDK style run by EOY.

0 · Reply

Ehri Apr. 27 at 4:33 AM

2 · Reply

Mjohns92 Apr. 27 at 4:31 AM

$SLS Crazy this was just 4 months ago. What a wild ride it's been and will continue to be

0 · Reply

ellenroberts337 Apr. 27 at 4:27 AM

$SLS Analyst target price update for today @ellenroberts337

0 · Reply

55X_ROI_Q1_2026 Apr. 27 at 4:27 AM

$SLS Max Value -- Buyout Will Come After Gps P3 results. a positive P3 Result is worth $40B to Big Pharma... Expect this $5 Share Price to Double, at least in the run up to that Mountain of Value.

0 · Reply

WangSLO Apr. 27 at 4:21 AM

$SLS

2 · Reply

WolfCola Apr. 27 at 4:19 AM

$SLS it would have been better if the dilution was somehow tied to the success of the drug. Would have been better for morale

0 · Reply

ValueIntelligenceAnalyst Apr. 27 at 4:17 AM

$SLS biotech name with big upside potential tied to trial results and FDA progress

1 · Reply

55X_ROI_Q1_2026 Apr. 27 at 4:15 AM

$SLS

0 · Reply

DrTwit Apr. 27 at 4:06 AM

$SLS There is no need whatsoever to expand the equity plan by 20M. We're not going to commercialize alone. No one wants that. Shareholders don't want it. BP sees right through it. Adding 20M RSUs ain't gonna change that. The move is a bidding war. Not a transparent bluff. Quit playing amateur hour poker and do your job. No to proposal 3.

2 · Reply

BioRich Apr. 27 at 4:03 AM

$SLS Given the drama hype that $SLS relied on to get $SLS SP artificially inflated into the $5's is fading fast, I believe announcement of the 80th event is a non-event SP-related. The reason being the 80th event is not a mystery anymore and at this point, all bets have been placed (figuratively speaking). Seeing it could be well over a month for results to come out, there's an opportunity for $SLS to get driven down hard as it would now be "Go time" and not "Pump Hope" time, which is where we are now. Talk is fun, but will the Rope Hats on this board actually right their money with $SLS or quietly take profit? I suggest the latter. Cheers!

0 · Reply

OnTheBalance Apr. 27 at 4:00 AM

$SLS Clearly stated by the CEO... Carpetbagging Shorts can blow their "non-brains" to smithereens.. Watch them post all night 🤣 🤣 🤣 🤣 🤣 🤣 🤣 🤣 🤣

0 · Reply

BioRich Apr. 27 at 3:59 AM

$SLS So it appears that $SLS is not happy with what they are seeing in the REGAL P3 trial and are trying to maintain investor attention as $SLS is on the cusp of a the hype high wearing off. Distractions, like updating the trial status for the Expanded Access Program (EAP), which actually signals they want subjects to start looking at "non-clinical" means to get GPS. That's very Bearish in my opinion, especially based on the timing.

1 · Reply

SLS009 Apr. 27 at 3:58 AM

$SLS Great news on the way Early on the morning or imminent.

2 · Reply

Macme Apr. 27 at 3:57 AM

$SLS The 20 Million Share Proposal The CEO is actively urging shareholders to approve a proposal at the June 16, 2026, Annual Meeting to add 20 million shares to the company's equity incentive plan. The Necessity: The company has nearly exhausted its current pool, with only about 8,000 shares remaining. The "Bulwark" Strategy: Some analysts and investors view this move as "proactive housekeeping." By securing more shares and potentially opening an At-The-Market (ATM) facility, the company signals it is not in a desperate cash position, which can improve its bargaining power in potential buyout negotiations.

1 · Reply

OnTheBalance Apr. 27 at 3:57 AM

$SLS Wow .... adult diapers exploding tonight .... non stop VD

0 · Reply

LongLongStock Apr. 27 at 3:52 AM

$SLS i think the best investment is to add around 1000 shares each month they don't announce the 80th event. because there is a higher chance of success :P

0 · Reply

WangSLO Apr. 27 at 3:50 AM

$SLS someone posted here over the weekend that the study website had posted that there was a study update, but that the update was unknown. Can someone confirm?

1 · Reply

Gypsey Apr. 27 at 3:45 AM

$SLS just for curiosity sake, if gps/sls009 proves to be a generationally groundbreaking cancer therapy, can anyone seeing the US govt jumping in to assist an american buyer and how could that play out?

1 · Reply

BioRich Apr. 27 at 3:39 AM

$SLS Another SLSer pumping and grasping for straws. Pumps "changes" to the EAP, but doesn't know what was changed. Then makes conclusions and opinions based on things they didn't even know what they meant. Seems about right for the $SLS board. Truly gullible, naive and herd mentality. Tough to watch. At least the $SLS CEO has the right audience to keep "this" going. Cheers!

1 · Reply

peacewealth7447 Apr. 27 at 3:28 AM

$SLS

0 · Reply

Market Cap	800.94M
Revenue (ttm)	0.00
Net Income (ttm)	-26.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,225,700
Avg Vol	6,643,928
Day's Range	N/A - N/A
Shares Out	179.58M
Stochastic %K	19%
Beta	2.22
Analysts	Sell
Price Target	$10.00